Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

TSXV:RP - Post Discussion

Replicel Life Sciences Inc > Twitter Update
View:
Post by Ingiboy on Mar 23, 2022 3:03pm

Twitter Update

Now that I have time to digest this recent "Update" on March 18th followed 4 days later by a private placement of 8,333,333 shares is a typical move by Replicel.  The natives were screaming for some sort of update  so let's give them afew meaningless crumbs before we hit them with the dilution.

We were expecting some type of timeline or outright announcement regarding seeking FDA Approval for the Dermal Injector but what did we get:  "data pouring in".   In October they made an announcement that the testing phase would be performed at the Monasterium lab and would take approx. 3 months.  That is long gone but yet they are still testing the device.  One might draw the conclusion that the device is far from ready for FDA Approval and this update was merely "kicking the can down the road" which places them in a financial crunch thus yet another private placement.

I try to be positive here but I have long stopped drinking the Kool-aide.  By the way what the hell is happening with this Shiseido Arbitration ?  It has been 6 months since the Arbitration was announced in Oct. 2021. On Dec. 21st 2021 Replicel tweeted:
"We have now terminated Shiseido's license to RCH-01. In the context of our arbitration, this provides RepliCel with the widest array of remedies including damages, return of license, etc. Nothing prevents the parties from settling this dispute any time."
Well I guess an early settlement is out of the question for Shiseido
Comment by toniZ1 on Mar 23, 2022 3:45pm
lets see who got those shares, then we know better. the arbitration timeframe was 6-12 months or any time.... I don't see that Shiseido setups a LAB, runs a 2nd study and then drops everything. Guess we will get an outcome within the next 3 months.  Any other good news is very welcome, but I dont expect any.
Comment by Ingiboy on Mar 23, 2022 4:07pm
The Arbitration process must be completed by the end of 12 months from filing.  That doesn't mean the Arbitrator would necessarily take that long for the ruling let alone a settlement by the two parties. I think if it s going to arbitration we could see something soon. From the Dec. 14th tweet: "Quick update on the arbitration with Shiseido. Things are proceeding on schedule and ...more  
Comment by hurko5 on Mar 23, 2022 3:55pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities